In vivo effect of a vitamin D-3 analog, EB1089, on acute myelogenous leukemia.

被引：0
|
作者：
Lee, YY
Park, WH
Seol, JG
Kim, ES
Jung, CW
Binderup, L
Koeffler, HP
Kim, BK
机构：
[1] HAN YANG UNIV HOSP,DEPT INTERNAL MED,SEOUL,SOUTH KOREA
[2] SEOUL NATL UNIV,COLL MED,SEOUL,SOUTH KOREA
[3] CHUNG ANG UNIV HOSP,SEOUL 156756,SOUTH KOREA
[4] LEO PHARMACEUT PROD,DK-2750 BALLERUP,DENMARK
[5] UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,LOS ANGELES,CA 90048
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：833 / 833
页数：1
相关论文
共 50 条
  • [21] Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089
    Zhang, XH
    Jiang, F
    Li, PF
    Li, CR
    Ma, QP
    Nicosia, SV
    Bai, WL
    CLINICAL CANCER RESEARCH, 2005, 11 (01) : 323 - 328
  • [22] Metabolism of the vitamin D analog EB 1089: Identification of in vivo and in vitro liver metabolites and their biological activities
    Kissmeyer, AM
    Binderup, E
    Binderup, L
    Hansen, CM
    Andersen, NR
    Makin, HLJ
    Schroeder, NJ
    Shankar, VN
    Jones, G
    BIOCHEMICAL PHARMACOLOGY, 1997, 53 (08) : 1087 - 1097
  • [23] The vitamin D receptor agonist EB1089 can exert its antiviral activity independently of the vitamin D receptor
    Jaratsittisin, Janejira
    Sornjai, Wannapa
    Chailangkarn, Thanathom
    Jongkaewwattana, Anan
    Smith, Duncan R.
    PLOS ONE, 2023, 18 (10):
  • [24] Fluorinated vitamin D-3 analog with in vivo anticancer activity
    Iseki, K
    Kobayashi, Y
    BIOMEDICAL FRONTIERS OF FLUORINE CHEMISTRY, 1996, 639 : 214 - 227
  • [25] Metabolism of the vitamin D analog EB1089 by cultured human cells: Redirection of hydroxylation site to distal carbons of the side-chain
    Shankar, VN
    Dilworth, FJ
    Makin, HLJ
    Schroeder, NJ
    Trafford, DJH
    Kissmeyer, AM
    Calverley, MJ
    Binderup, E
    Jones, G
    BIOCHEMICAL PHARMACOLOGY, 1997, 53 (06) : 783 - 793
  • [26] Metabolism of the vitamin D3 analogue EB1089 alters receptor complex formation and reduces promoter selectivity
    Quack, M
    Hansen, CM
    Binderup, E
    Kissmeyer, AM
    Carlberg, C
    BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (04) : 607 - 614
  • [27] A phase II trial of the vitamin D analogue seocalcitol (EB1089) in patients with inoperable pancreatic cancer
    Evans T.R.J.
    Colston K.W.
    Lofts F.J.
    Cunningham D.
    Anthoney D.A.
    Gogas H.
    De Bono J.S.
    Hamberg K.J.
    Skov T.
    Mansi J.L.
    British Journal of Cancer, 2002, 86 (5) : 680 - 685
  • [28] EFFECTS OF EB1089, A NEW SYNTHETIC VITAMIN-D ANALOG, ON THE ESTROGEN-RESPONSIVE GROWTH OF HUMAN BREAST-CANCER CELLS
    JAMES, SY
    MACKAY, AG
    OFORIKURAGU, EA
    BINDERUP, L
    COLSTON, KW
    JOURNAL OF ENDOCRINOLOGY, 1992, 135 : P21 - P21
  • [29] Structural variants of the vitamin D analogue EB1089 reduce its ligand sensitivity and promoter selectivity
    Quack, M
    Clarin, A
    Binderup, E
    Björkling, F
    Hansen, CM
    Carlberg, C
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1998, 71 (03) : 340 - 350
  • [30] Vitamin D-3 analogue (EB 1089) inhibits in vitro cellular proliferation of human colon cancer cells
    Akhter, J
    Goerdel, M
    Morris, DL
    BRITISH JOURNAL OF SURGERY, 1996, 83 (02) : 229 - 230
12345